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    Thirty－seven patients with prostatic cancer who were treated at our clinic during 5 years frem
May 1975 to May 1980 were reviewed． A study was rnade with emphasis on the diagnostic and ．thera－
peutic usefulness of transrectal ultrasonotomogra．phy and the measurement of serum prosta±ic acid
phosphatase by radioimpaunoassay， which was compared with that of enzyme assay （？enyl phosphate）．
    1． Ultrasonographic diagnosis agreed with histological results fQr 27 （900／．） of 30 cases． Of 8
cases which could not be diagnosed by’any other examination， 6 cases were suspected Dr established
the diagnosis of prostatic cancer by transrectal ultrasonotomography． This examination showed its
possibility to diagnose early cancer of the prostate．
   2． Serum from 15 patients with prostatic cancer and 52 patients without prostatic cancer were
studied by radioimmunoassay （GammaDab＠f radioimmunoassay Kit） and enzyme assay using penyl－
phosphate． When the upper limit for radioimmunoassay was set at 1．64 ng／ml （mean十2S．D．） from
the patients without prostatic cancer， 2 untreated cases showed positive for radioimmunoassay test
though their enzymc assay were false－negative．
   One case was an intracapsular prostatic cancer． The other was an advanced prostatic cancer
with bone metastasis． The assay of the recurrent or treating patients （measured a week after the
284 泌尿紀要27巻 3号 1981年
beginning of ttieatment） were also the same result． We cenclud．e that immunological detection of


























































































































臨 床 診 断


































































 77 1．6755・一76 O．71±O．87




28 ・一 63 O．61 ±O． 25
16－72 O．80±O，90




























































    しprostatic 曜prostat｝C
cancer    聖cancer    「
         コ                                 Female IAfter total：Urinary  IB．P．H．＆ IOtherbenign
    ；・y・・eG・…i・・act t・…i・・・・・・・・…idi3ea器。1。）
    【              8              に              ，








PAP Serum StandardとPatienV s Serum
Sample（O，1．O，3．0，30．0， sample各IOOμ1＞
          ．
Goat Anti－PAP Serum I OOμiを加え，
18hr． lncubation （20一”27’C）
Iasl－PAP I OOμ1を加え，3hr． Incubation
              （20一一27℃）
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肝機能異常を改善する e － e e e e
レ適応症 慢性肝疾患における肝機能異常の改善」
      とくに，GOT， GPT，γ一GTPの改…善効果が
      著しい。
 レ用法・用量 1日1回，40m tを静脈内に注射する。
        年齢，症状により適宜増減する。
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